Dolutegravir as first- or second-line treatment for children living with HIV: 240-week follow-up of the ODYSSEY randomised trial

11 May, 2026

Authors: Mujuru HA, White E, Kekitiinwa AR, Lugemwa A, Kityo C, Violari A, Ahimbisibwe GM, Variava E, Archary M, Cotton M, Ounchanum P, Puthanakit T, Kanjanavanit S, Ngampiyaskul C, Kobbe R, Bandi S, Epaiza C, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Kaudha E, Cressey TR, Giaquinto C, Jafta L, Bamford A, Rojo P, Gibb DM, Turkova A, Ford D, on behalf of the ODYSSEY Trial Team

Published inOpen Forum Infectious Diseases